Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212215 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CA1CA2KMT2ALMNA | |
| SCHEMBL7438726 | 0.79 | NPC1 (0.45) | IDO1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL9065846 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ACNR2LMNA | |
| SCHEMBL1413274 | 0.78 | FABP7 (0.44) | IDO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL6285272 | 0.77 | CNR2 (0.50) | ALDH1A1MEN1KMT2ACNR2LMNA | |
| SCHEMBL7216770 | 0.77 | FFAR1 (0.53) | ALDH1A1KMT2AHTTCNR2LMNA | |
| SCHEMBL5484162 | 0.77 | ALDH1A1 (0.49) | IDO1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL5183992 | 0.76 | ATM (0.55) | ALDH1A1CA1CA2MEN1KMT2A | |
| SCHEMBL5053407 | 0.76 | CYP19A1 (0.36) | IDO1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL1521950 | 0.76 | CA1 (0.50) | ALDH1A1CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | MACROGENICS, INC. (US) | 2023-02-28 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | MACROGENICS, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| CN-115484982-A | Methods for using B7-H3 antibody-drug conjugates, alone or in combination | 宏观基因有限公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | disclosed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | disclosed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | disclosed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | IDO1 76/4885F2 2805/4885PLAU 4781/4885 |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | CD274, CD2, CD22 | IDO1 76/4885F2 2805/4885PLAU 4781/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | IDO1 2204/4885F2 1354/4885PLAU 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.